BBH – VanEck Biotech ETF
VanEck Biotech ETF (BBH) is a Health ETF, issued by VanEck, $390M in assets, 0.35% expense ratio.
Returns as of Oct 23, 2026: 1 week +2.2%, 1 year +22.3%.
Invests 80% in Biotech Index securities, including U.S.-listed biotechnology companies, medium-cap and foreign firms. Non-diversified.
Top holdings
- AMGN – Amgen Inc, 15.1%
- GILD – Gilead Sciences Inc, 14.5%
- VRTX – Vertex Pharmaceuticals Inc, 8.8%
- REGN – Regeneron Pharmaceuticals Inc, 7.3%
- IQV – IQVIA Holdings Inc, 4.8%
- ARGX – argenx NV ADR, 4.5%
- NTRA – Natera Inc, 4.3%
- ALNY – Alnylam Pharmaceuticals Inc, 4.0%
- INSM – Insmed Inc, 3.8%
- BGNE – BeiGene Ltd, 3.5%
- BIIB – Biogen Inc, 2.9%
- UTHR – United Therapeutics Corporation, 2.8%
- ILMN – Illumina Inc, 2.8%
- ICLR – ICON PLC, 2.4%
- MRNA – Moderna Inc, 2.2%
- EXAS – EXACT Sciences Corporation, 2.2%
- INCY – Incyte Corporation, 2.1%
- BNTX – BioNTech SE, 2.1%
- NBIX – Neurocrine Biosciences Inc, 1.8%
- TECH – Bio-Techne Corp, 1.5%
- CRL – Charles River Laboratories, 1.5%
- TEM – Tempus AI, Inc. Class A Common Stock, 1.3%
- RGEN – Repligen Corporation, 1.3%
- BMRN – Biomarin Pharmaceutical Inc, 1.1%